Lacosamide

Bezeichnung:Lacosamide

CAS-Nr175481-36-4

Englisch Name:Lacosamide

CBNumberCB41011740

SummenformelC13H18N2O3

Molgewicht250.29

MOL-Datei175481-36-4.mol

Lacosamide physikalisch-chemischer Eigenschaften

Schmelzpunkt	141-143?C
alpha	D23 +16.0° (c = 1 in CH3OH)
Siedepunkt	536.4±50.0 °C(Predicted)
Dichte	1.120±0.06 g/cm3(Predicted)
Flammpunkt	2℃
storage temp.	Refrigerator
Löslichkeit	DMF: 20 mg/ml; DMSO: 20 mg/ml; Ethanol: 20 mg/ml; PBS (pH 7.2): 2 mg/ml
Aggregatzustand	A crystalline solid
pka	14.19±0.46(Predicted)
InChI	InChI=1S/C13H18N2O3/c1-10(16)15-12(9-18-2)13(17)14-8-11-6-4-3-5-7-11/h3-7,12H,8-9H2,1-2H3,(H,14,17)(H,15,16)/t12-/m1/s1
InChIKey	VPPJLAIAVCUEMN-GFCCVEGCSA-N
SMILES	C(NCC1=CC=CC=C1)(=O)[C@H](NC(C)=O)COC
CAS Datenbank	175481-36-4

Sicherheit

Kennzeichnung gefährlicher	F,Xn
R-Sätze:	11-20/21/22-36
S-Sätze:	16-26-36/37
RIDADR	UN 1648 3 / PGII
WGK Germany	2
HS Code	2924296000

Gefahreninformationscode (GHS)

Lacosamide Chemische Eigenschaften,Einsatz,Produktion Methoden

Beschreibung
Although epilepsy is a neurological disorder with varying etiology and severity, the common feature is unprovoked, recurring seizures. Whether classified as generalized, involving both cerebral hemispheres, or partial with only localized portions of brain participation at onset, effective treatment relies on accurate assessment of syndrome type to optimally decrease the frequency, duration, and severity of seizures. The latest weapon against partial onset epilepsy is lacosamide, formerly known as harkoseride and erlosamide. The data also indicate that lacosamide binds to collapsing response mediator protein 2 (CRMP2); CRMP2 is involved in neuronal differentiation, control of axonal outgrowth, and possibly epileptogenesis. Furthermore, lacosamide is heralded as having a dual mode of action as it has also displayed efficacy against diabetic neuropathy, possibly as a result of stabilization of neuronal hyperexcitability. Currently,lacosamide is approved as adjunctive treatment of partial onset seizures in patients 17 years or older and is in development as a monotherapy for epilepsy and for neuropathic pain.
Beschreibung
Lacosamide selectively enhances sodium channel slow inactivation without affecting fast inactivation. It is effective in multiple rodent models of seizure activity. The neuroprotective effects of lacosamide are also attributed to its ability to modulate collapsin response mediator protein 2 (CRMP-2), a member of the semaphorin signal transduction pathway. Formulations containing lacosamide have been used as an adjunctive or monotherapy for focal-onset seizures but, at higher doses, have a low potential for abuse. Lacosamide is regulated as a Schedule V compound in the United States.
Chemische Eigenschaften
White to Off-White Solid
Originator
Harris FRC (United States)
Verwenden
A potent anticonvulsant.
Definition
ChEBI: Lacosamide is a N-acyl-amino acid.
Trademarks
Vimpat
Synthese
The most common adverse events were diplopia, headache, dizziness, and nausea. As typical with AEDs, lacosamide may increase the risk of suicidal thoughts or behavior. Patients should, therefore, be monitored for the emergence or worsening of depression. Caution should also be exercised in patients with known conduction problems or severe cardiac disease (myocardial ischemia or heart failure) since dose-dependent prolongations in PR interval have been observed in clinical studies.

Lacosamide Anbieter Lieferant Produzent Hersteller Vertrieb Händler.

175481-36-4, Lacosamide Verwandte Suche:

Send Inquriy